Nina Greilert

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: FRONTIERS IN IMMUNOLOGY. 2024;15:1346749

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum

Bladh O; Aguilera K; Marking U; Kihlgren M; Norin NG; Smed-Sorensen A; Chen MS; Klingstrom J; Blom K; Russell MW; Havervall S; Thalin C; Aberg M
Article: NATURE COMMUNICATIONS. 2023;14(1):1577

Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers

Marking U; Havervall S; Norin NG; Bladh O; Christ W; Gordon M; Ng H; Blom K; Phillipson M; Mangsbo S; Alm JJ; Smed-Sorensen A; Nilsson P; Hober S; Aberg M; Klingstroem J; Thalin C
Article: VACCINES. 2022;10(3):359

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Marking U; Havervall S; Greilert-Norin N; Ng H; Blom K; Nilsson P; Phillipson M; Hober S; Nilsson C; Mangsbo S; Christ W; Klingstrom J; Gordon M; Aberg M; Thalin C
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2022;11(4):e1388

Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

Havervall S; Marking U; Greilert-Norin N; Gordon M; Ng H; Christ W; Phillipson M; Nilsson P; Hober S; Blom K; Klingstrom J; Mangsbo S; Aberg M; Thalin C
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):72-80

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19

Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Manberg A; Marking U; Lauren I; Gabrielsson L; Salomonsson A-C; Aguilera K; Kihlgren M; Mansson M; Rosell A; Hellstrom C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Aberg M; Hedhammar M; Tegel H; Donnes P; Phillipson M; Nilsson P; Klingstrom J; Mangsbo S; Hober S; Thalin C
Article: STROKE. 2021;52(10):3082-3087

Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke Results From EFFECTS, a Randomized Controlled Trial

Lundstrom E; Isaksson E; Greilert Norin N; Nasman P; Wester P; Martensson B; Norrving B; Wallen H; Borg J; Hankey GJ; Hackett ML; Mead GE; Dennis MS; Sunnerhagen KS
Article: EBIOMEDICINE. 2021;70:103523

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson A-C; Hellstrom C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingstrom J; Hober S; Nilsson P; Aberg M; Thalin C

Alla övriga publikationer

Letter: LANCET REGIONAL HEALTH-EUROPE. 2024;38:100872

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023

Aguilera K; Bladh O; Marking U; Norin NG; Rihani A; Ujvari D; Ning FC; Klingstroem J; Havervall S; Aberg M; Blom K; Alm JJ; Thalin C
Letter: LANCET INFECTIOUS DISEASES. 2024;24(2):e80-e81

Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2023;389(17):1626-1628

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection

Bladh O; Greilert-Norin N; Havervall S; Marking U; Aguilera K; Alm JJ; Blom K; Aberg M; Klingstrom J; Thalin C
Letter: LANCET REGIONAL HEALTH-EUROPE. 2023;33:100725

Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden

Blom K; Bladh O; Havervall S; Marking U; Norin NG; Alm JJ; Klingstrom J; Thalin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(8):e272-e273

Mucosal IgA protects against BQ.1 and BQ.1.1 infection

Marking U; Bladh O; Havervall S; Greilert-Norin N; Gordon M; Alm JJ; Blom K; Aberg M; Klingstrom J; Thalin C
Letter: LANCET MICROBE. 2023;4(7):e488

Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose

Bladh O; Marking U; Havervall S; Norin NG; Aguilera K; Hober S; Smed-Soerensen A; Gordon M; Blom K; Aberg M; Klingstrom J; Thalin C
Letter: LANCET INFECTIOUS DISEASES. 2023;23(2):150-152

7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection

Marking U; Bladh O; Havervall S; Svensson J; Greilert-Norin N; Aguilera K; Kihlgren M; Salomonsson A-C; Mansson M; Gallini R; Kriegholm C; Bacchus P; Hober S; Gordon M; Blom K; Smed-Sorensen A; Aberg M; Klingstrom J; Thalin C
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(14):1333-1336

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

Havervall S; Marking U; Svensson J; Greilert-Norin N; Bacchus P; Nilsson P; Hober S; Gordon M; Blom K; Klingstrom J; Aberg M; Smed-Sorensen A; Thalin C
Letter: EMERGING INFECTIOUS DISEASES. 2022;28(10):2119-2121

Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022

Blom K; Havervall S; Marking U; Norin NG; Bacchus P; Groenheit R; Brave A; Thalin C; Klingstrom J
Letter: LANCET INFECTIOUS DISEASES. 2022;22(7):943-945

Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection

Blom K; Marking U; Havervall S; Norin NG; Gordon M; Garcia M; Tecleab T; Christ W; Forsell M; Phillipson M; Nilsson P; Mangsbo S; Hober S; Aberg M; Klingstrom J; Thalin C
Preprint: MEDRXIV. 2022

High prevalence of long-term olfactory disorders in healthcare workers after COVID-19: a case-control study

Frasnelli J; Tognetti A; Winter A; Thunell E; Olsson M; Greilert N; Olofsson J; Havervall S; Thålin C; Lundström J

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI